02.02.2010 • NewsDuPontphotovoltaic

Dupont Opens Photovoltaic Application Facility in Geneva

Dupont has opened the Meyrin Photovoltaic Application Laboratory at its European Technical Center in Geneva in order to address the needs for the fast-growing photovoltaic market, the company said in a statement.

The Meyrin Photovoltaic Application Lab will operate as an open center, enabling technological exchanges and research collaborations between Dupont and customers, industrial partners, institutes and academia. The lab is designed to advance state-of-the-art solar module design, accelerate time to market in photovoltaic innovation and deliver cost-effective, high-performance solutions for the photovoltaic industry.

A new building-integrated photovoltaic (BIPV) panel system that replaces tile or slate roofs is an example of open innovation. This new innovation was developed at the lab in collaboration with Dupont Building Innovations, Dupont Performance Polymers and industry partners. The company said it significantly improves the ease and speed of installation, offers high-energy efficiency, exceptional water tightness and superior aesthetics to the building. The system was initially developed for the French market where it will be commercialized in the first quarter of 2010. In a second phase, the product will be commercialized in other Southern European markets.

 

Company

DuPont Company

101.Beech St. 16-1216
19880 Wilmington

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.